Patients
cancer, death, tumor
ONCOLOGY, CANCER, TUMOR
Of 709 patients randomized in CheckMate 274 (353 to nivolumab and 356 to placebo), 49 were Japanese and included in the present analyses. Twenty-seven were allocated to nivolumab and 22 to placebo per the central randomization process.The characteristics of the Japanese patients and the overall population are summarized in Demographic and clinical characteristics of all randomized Japanese patients at baselineECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death ligand 1; IVRS, interactive voice-response system.




Demographic and clinical characteristics of all randomized patients at baselineReprinted from Ref. (




In the Japanese cohort, tumor PD-L1 expression level was 1% or more in 11 patients in the nivolumab group and in 8 patients in the placebo group. Some numerical differences were observed between these two groups for the following baseline characteristics: age 65 years or greater, ECOG PS, cancer location, lymph node status and cisplatin-based neoadjuvant chemotherapy (